Trial Profile
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Upadacitinib (Primary) ; Adalimumab
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms SELECT-COMPARE
- Sponsors AbbVie; AbbVie Germany
- 15 Nov 2023 Results of an integrated analysis assessing gene expression and methylation identifies biomarkers associated with mode of action of Upadacitinib from three phase 3 clinical studies: SELECT-BEYOND, SELECT-COMPARE and SELECT-NEXT presented at the ACR Convergence 2023
- 15 Nov 2023 Results assessing direct and indirect (ie, by inflammation surrogates) effects of treatment with upadacitinib or adalimumab vs placebo on pain in pts with RA, were presented at the ACR Convergence 2023.
- 12 Jun 2023 Results of post-hoc pooled analysis of 6 studies (NCT02706873, NCT02675426, NCT02629159, NCT02706951, NCT02706847 and NCT03086343) assessing potential risk of upadacitinib in a similar RA population, published in the Annals of the Rheumatic Diseases.